Advertisement
Screener

MeiraGTx Holdings plc (MGTX) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

MeiraGTx Holdings plc Operating Cash Flow

MeiraGTx Holdings plc (MGTX) reported Operating Cash Flow of -$20.73 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13

  • MeiraGTx Holdings plc net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$38.54M.
  • MeiraGTx Holdings plc net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $17.81M.
  • MeiraGTx Holdings plc net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $46.63M.
  • MeiraGTx Holdings plc net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$12.21M.
  • MeiraGTx Holdings plc net cash provided by (used in) operating activities for fiscal 2025 was -$46.36M.
  • MeiraGTx Holdings plc net cash provided by (used in) operating activities for fiscal 2024 was -$104.50M.
  • MeiraGTx Holdings plc net cash provided by (used in) operating activities for fiscal 2023 was -$105.36M.
  • MeiraGTx Holdings plc net cash provided by (used in) operating activities for fiscal 2022 was -$73.10M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 3 month as first filedNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 6 month as first filedNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 9 month as first filedNet Cash Provided by (Used in) Operating Activities 12 monthNet Cash Provided by (Used in) Operating Activities 12 month as first filed
2026-06-30-$38.54M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
-$20.73M
10-Q · filed 2026-08-13
$25.90M
derived: sum of 3 quarters · filed 2026-08-13
$13.69M
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31$17.81M
10-Q · filed 2026-05-14
$64.44M
derived: sum of 2 quarters · filed 2026-05-14
$52.23M
derived: sum of 3 quarters · filed 2026-05-14
$8.28M
derived: sum of 4 quarters · filed 2026-08-13
2025-12-31$46.63M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
$34.42M
derived: sum of 2 quarters · filed 2026-03-30
-$9.53M
derived: sum of 3 quarters · filed 2026-08-13
-$46.36M
10-K · filed 2026-03-30
2025-09-30-$12.21M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
-$56.16M
derived: sum of 2 quarters · filed 2026-08-13
-$92.99M
10-Q · filed 2025-11-13
-$116.27M
derived: sum of 4 quarters · filed 2026-08-13
2025-06-30-$43.95M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
-$80.78M
10-Q · filed 2026-08-13
-$104.05M
derived: sum of 3 quarters · filed 2026-08-13
-$129.07M
derived: sum of 4 quarters · filed 2026-08-13
2025-03-31-$36.83M
10-Q · filed 2026-05-14
-$60.10M
derived: sum of 2 quarters · filed 2026-05-14
-$85.13M
derived: sum of 3 quarters · filed 2026-05-14
-$104.58M
derived: sum of 4 quarters · filed 2026-05-14
2024-12-31-$23.28M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
-$48.30M
derived: sum of 2 quarters · filed 2026-03-30
-$67.75M
derived: sum of 3 quarters · filed 2026-03-30
-$104.50M
10-K · filed 2026-03-30
2024-09-30-$25.02M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
-$44.48M
derived: sum of 2 quarters · filed 2025-11-13
-$81.22M
10-Q · filed 2025-11-13
-$95.77M
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30-$19.46M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14
-$56.20M
10-Q · filed 2025-08-14
-$70.74M
derived: sum of 3 quarters · filed 2025-08-14
-$95.16M
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31-$36.74M
10-Q · filed 2025-05-13
-$51.29M
derived: sum of 2 quarters · filed 2025-05-13
-$75.70M
derived: sum of 3 quarters · filed 2025-05-13
-$104.71M
derived: sum of 4 quarters · filed 2025-05-13
2023-12-31-$14.55M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13
-$38.96M
derived: sum of 2 quarters · filed 2025-03-13
-$67.97M
derived: sum of 3 quarters · filed 2025-03-13
-$105.36M
10-K · filed 2025-03-13
2023-09-30-$24.41M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13
-$53.43M
derived: sum of 2 quarters · filed 2024-11-13
-$90.82M
10-Q · filed 2024-11-13
-$107.08M
derived: sum of 4 quarters · filed 2024-11-13
2023-06-30-$29.01M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12
-$66.40M
10-Q · filed 2024-08-12
-$82.67M
derived: sum of 3 quarters · filed 2024-08-12
-$103.40M
derived: sum of 4 quarters · filed 2024-08-12
2023-03-31-$37.39M
10-Q · filed 2024-05-09
-$53.66M
derived: sum of 2 quarters · filed 2024-05-09
-$74.39M
derived: sum of 3 quarters · filed 2024-05-09
-$102.19M
derived: sum of 4 quarters · filed 2024-05-09
2022-12-31-$16.27M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15
-$36.99M
derived: sum of 2 quarters · filed 2024-03-15
-$64.80M
derived: sum of 3 quarters · filed 2024-03-15
-$73.10M
10-K · filed 2024-03-15
2022-09-30-$20.73M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14
-$48.53M
derived: sum of 2 quarters · filed 2023-11-14
-$56.83M
10-Q · filed 2023-11-14
-$38.00M
derived: sum of 4 quarters · filed 2023-11-14
2022-06-30-$27.81M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
-$36.10M
10-Q · filed 2023-08-10
-$17.28M
derived: sum of 3 quarters · filed 2023-08-10
-$34.46M
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31-$8.30M
10-Q · filed 2023-05-11
$10.53M
derived: sum of 2 quarters · filed 2023-05-11
-$6.65M
derived: sum of 3 quarters · filed 2023-05-11
-$27.91M
derived: sum of 4 quarters · filed 2023-05-11
2021-12-31$18.83M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14
$1.65M
derived: sum of 2 quarters · filed 2023-03-14
-$19.62M
derived: sum of 3 quarters · filed 2023-03-14
-$10.53M
10-K · filed 2023-03-14
2021-09-30-$17.18M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10
-$38.44M
derived: sum of 2 quarters · filed 2022-11-10
-$29.36M
10-Q · filed 2022-11-10
-$58.92M
derived: sum of 4 quarters · filed 2022-11-10
2021-06-30-$21.26M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11
-$12.18M
10-Q · filed 2022-08-11
-$41.74M
derived: sum of 3 quarters · filed 2022-08-11
-$50.88M
derived: sum of 4 quarters · filed 2022-08-11
2021-03-31$9.09M
10-Q · filed 2022-05-12
-$20.48M
derived: sum of 2 quarters · filed 2022-05-12
-$29.62M
derived: sum of 3 quarters · filed 2022-05-12
-$42.50M
derived: sum of 4 quarters · filed 2022-05-12
2020-12-31-$29.56M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10
-$38.70M
derived: sum of 2 quarters · filed 2022-03-10
-$51.58M
derived: sum of 3 quarters · filed 2022-03-10
-$63.97M
10-K · filed 2022-03-10
-$63.97M
10-K · filed 2021-03-11
2020-09-30-$9.14M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10
-$22.02M
derived: sum of 2 quarters · filed 2021-11-10
-$34.41M
10-Q · filed 2021-11-10
-$34.41M
10-Q · filed 2020-11-05
-$56.38M
derived: sum of 4 quarters · filed 2021-11-10
2020-06-30-$12.88M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11
-$25.26M
10-Q · filed 2021-08-11
-$25.26M
10-Q · filed 2020-08-06
-$47.24M
derived: sum of 3 quarters · filed 2021-08-11
-$65.64M
derived: sum of 4 quarters · filed 2021-08-11
2020-03-31-$12.38M
10-Q · filed 2021-05-11
-$12.38M
10-Q · filed 2020-05-07
-$34.36M
derived: sum of 2 quarters · filed 2021-05-11
-$52.76M
derived: sum of 3 quarters · filed 2021-05-11
-$74.51M
derived: sum of 4 quarters · filed 2021-05-11
2019-12-31-$21.97M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11
-$40.38M
derived: sum of 2 quarters · filed 2021-03-11
-$62.12M
derived: sum of 3 quarters · filed 2021-03-11
$20.04M
10-K · filed 2021-03-11
2019-09-30-$18.41M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
-$40.15M
derived: sum of 2 quarters · filed 2020-11-05
$42.02M
10-Q · filed 2020-11-05
$30.55M
derived: sum of 4 quarters · filed 2020-11-05
2019-06-30-$21.74M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06
$60.42M
10-Q · filed 2020-08-06
$48.95M
derived: sum of 3 quarters · filed 2020-08-06
$37.96M
derived: sum of 4 quarters · filed 2020-08-06
2019-03-31$82.17M
10-Q · filed 2020-05-07
$70.70M
derived: sum of 2 quarters · filed 2020-05-07
$59.70M
derived: sum of 3 quarters · filed 2020-05-07
$40.67M
derived: sum of 4 quarters · filed 2020-05-07
2018-12-31-$11.47M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11
-$22.46M
derived: sum of 2 quarters · filed 2020-03-11
-$41.49M
derived: sum of 3 quarters · filed 2020-03-11
-$58.89M
10-K · filed 2020-03-11
2018-09-30-$10.99M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07
-$30.02M
derived: sum of 2 quarters · filed 2019-11-07
-$47.42M
10-Q · filed 2019-11-07
-$51.13M
derived: sum of 4 quarters · filed 2019-11-07
2018-06-30-$19.03M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07
-$36.43M
10-Q · filed 2019-08-07
-$40.13M
derived: sum of 3 quarters · filed 2019-08-07
-$43.95M
derived: sum of 4 quarters · filed 2019-08-07
2018-03-31-$17.40M
10-Q · filed 2019-05-14
-$21.11M
derived: sum of 2 quarters · filed 2019-05-14
-$24.92M
derived: sum of 3 quarters · filed 2019-05-14
2017-12-31-$3.71M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26
-$7.52M
derived: sum of 2 quarters · filed 2019-03-26
-$18.06M
10-K · filed 2019-03-26
2017-09-30-$3.82M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08
-$14.35M
10-Q · filed 2018-11-08
2017-06-30-$10.53M
10-Q · filed 2018-08-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
Vor Biopharma Inc. (VOR)United States$1.091B1.60
Monte Rosa Therapeutics, Inc. (GLUE)United States$1.002B-12.81
Cullinan Therapeutics, Inc. (CGEM)United States$0.993B-5.72
Odyssey Therapeutics, Inc. (ODTX)United States$0.960B
Replimune Group, Inc. (REPL)United States$1.186B-3.13
Sana Biotechnology, Inc. (SANA)United States$0.886B-4.92
Candel Therapeutics, Inc. (CADL)United States$0.885B-8.86
Attovia Therapeutics, Inc. (ATTO)United States$0.828B
Solid Biosciences Inc. (SLDB)United States$0.802B-5.07
4D Molecular Therapeutics, Inc. (FDMT)United States$0.733B-4.10